Last reviewed · How we verify

Multiple Product PrEP Program

University of Alabama at Birmingham · FDA-approved active Small molecule

A program providing multiple antiretroviral formulations for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals.

A program providing multiple antiretroviral formulations for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals. Used for HIV pre-exposure prophylaxis (PrEP) in at-risk individuals without HIV infection.

At a glance

Generic nameMultiple Product PrEP Program
SponsorUniversity of Alabama at Birmingham
Drug classAntiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)
TargetHIV reverse transcriptase, HIV integrase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

The Multiple Product PrEP Program offers various FDA-approved PrEP medications (primarily tenofovir/emtricitabine-based regimens) through the University of Alabama at Birmingham to increase access and adherence to HIV prevention. These antiretrovirals work by inhibiting reverse transcriptase and integrase enzymes critical to HIV replication, providing protection when taken consistently before potential exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: